![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Structured Product Merrill Lynch Dow Jones Euro Stoxx 50 Index Mitts | NYSE:MLB | NYSE | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.97 | 0.00 | 01:00:00 |
RNS Number:6640L M.L. Laboratories PLC 29 May 2003 For immediate release 29 May 2003 ML REDUCES STAKE IN COBRA BIOMANUFACTURING PLC Total Raised from Divestment of Non-Core Manufacturing Businesses Now Exceeds #13.5m ML announces that it has agreed to sell 5 million shares in Cobra Biomanufacturing PLC ("CBM") for a consideration of #4 million before costs. The shares are being sold on behalf of ML by Collins Stewart which is also effecting a placing and open offer on behalf of CBM. S.W. Sim, Executive Chairman of ML stated: 'Shareholders will be aware that a significant proportion of our holding in CBM was subject to a lock-in arrangement until June 2004. The placing and open offer announced by CBM today presents us with the opportunity to reduce our holding earlier than originally anticipated and realise additional funds for the Company. The disposal proceeds will bring the total cash realised to date from the divestment of CBM via flotation on AIM in June 2002 to #7M and the total gross sum realised to date from our programme of divestment of non core manufacturing businesses to in excess of #13.5 million. The funds raised have improved our liquidity position considerably and enabled us to focus on the development of our pharmaceutical product pipeline'. ML has retained a holding of 1 million CBM shares (approx. 5%) which is currently valued at #800,000 and is not subject to any lock-in arrangements. For further information please contact: Mr. Stuart Sim Chairman, ML Laboratories PLC +44 (0) 1925 844 700 Kevin Smith Weber Shandwick Square Mile +44 (0) 20 7067 0700 Graham Herring Note to editors: ML is a biopharmaceutical product development company with a pipeline of future products targeted at specialist markets. ML's activities are supported by a growing income stream from marketed products it has successfully developed and licensed to other pharmaceutical companies which include Baxter, Shire and Celltech. New therapeutic products in clinical development include cancer treatments, a pain management compound prepared to enter Phase III studies, a preventative of sexually transmitted infections, including HIV and a phosphate binder to assist the management of kidney failure. ML's portfolio of early stage development projects includes unique polymer/drug molecules to provide safer and more potent cancer chemotherapy and technologies for use in the discovery and manufacture of biotechnology products. In addition ML provides inhaled drug delivery solutions to the global pharmaceutical industry through its dedicated respiratory subsidiary Innovata Biomed. This information is provided by RNS The company news service from the London Stock Exchange END MSCPUUAUAUPWUMB
1 Year Mitchells & Butlers Chart |
1 Month Mitchells & Butlers Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions